Varlilumab

N/A

Report date: 2026/02/06 20:01:23

Base Information

Drug NameVarlilumab
Drug Alias NameCDX-1127
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCD27 antigen inhibitors
TargetsCD27 antigen
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursCentral Nervous System Lymphoma +[41
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelldex Therapeutics
China Registration ClassN/A

Develop Information

Inactive CompaniesRutgers University
Active IndicationsSkin NeoplasmsGallbladder NeoplasmsBile Duct Neoplasms +[15
Inactive IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursCentral Nervous System Lymphoma +[26

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank